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Abstract: Primary hypertension in children is increasing in prevalence with many cases likely going undiagnosed. The prevalence is
currently estimated at between 3%–5% in the United States and may be higher in certain ethnic groups. Primary hypertension, once
felt to be rare in children, is now considered to be about five times more common than secondary hypertension. This review provides
information to guide physicians through an organized approach to: 1) screening children and adolescents for hypertension during routine
visits; 2) using normative percentile data for diagnosis and classification; 3) performing a clinical evaluation to identify the presence of
co-morbidities; 4) initiating a plan of care including subsequent follow-up blood pressure measurements, therapeutic lifestyle changes
and pharmacologic therapies.
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Introduction

The prevalence of hypertension in children and
adolescents has increased in the past several years,
likely as a result of the rise in childhood overweight
and obesity. The prevalence is currently estimated
at between 3%–5% in the United States and may be
higher in certain ethnic groups, such as non-Hispanic
blacks and Mexican Americans.1–3 This may actually
be an underestimate as some experts believe that clinicians fail to recognize high blood pressure in children
and adolescents.3 Unlike in the adult population
where absolute cutoffs exist based on observational
studies, classification of blood pressure in children
and adolescents is based on normative data derived
from a national database of 70,000 healthy children
in the US.4
Blood pressure in children is classified as:
(1) normal (systolic and diastolic blood pressure
[SBP and DBP respectively] ,90th percentile);
(2) pre-hypertension (SBP and DBP 90th to ,95th
percentile or exceeding 120/80); (3) Stage 1 hypertension (95th percentile to 99th plus 5 mmHg); and
(4) Stage 2 hypertension (.99th percentile plus
5 mmHg) based on sex, age and height on at least
three separate measurements.4 Patients are felt to
have “white-coat hypertension” when BP is normal
outside a medical provider’s office but 95th percentile or greater in the office. Children have hypertension when blood pressures are persistently elevated
greater than 140/90 or greater than the 95th percentile based on these classifications.
The Fourth Report on the Diagnosis, Evaluation,
and Treatment of High Blood Pressure in Children
and Adolescents is still the major reference point for
recommendations regarding the diagnosis and treatment of hypertension in children and adolescents.4
In 2009, the European Society of Hypertension
released updated guidelines on management of
high blood pressure in children and adolescents and
used the same criteria to define hypertension as the
Fourth Report.5 The guidelines suggest an emerging role for the use of ambulatory and home blood
pressure monitoring in children and adolescents for
the diagnosis of hypertension especially in children
with isolated clinic hypertension and assessment of
response to treatment.5 Isolated clinic hypertension
is defined as blood pressure measurements .95th
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percentile in the office and ,90th percentile in the
outpatient setting.4
Special considerations exist for measuring blood
pressure in children and adolescents. In general,
children greater than 3 years old should have their
blood pressure routinely measured during each
health care encounter. Blood pressure should be
measured by auscultation as BP normative data was
obtained using auscultation and there are many limitations to the use of automated oscillometric devices
in children.4,5 A study done after the release of the
Fourth Report recommendations involving 390 children at a pediatric hypertension clinic found that
74% of initial readings done at a standard vital sign
station were higher (13.2 ± 8.9 mmHg for SBP and
9.6 ± 7.6 mm Hg for DBP) than those obtained in
the examination room using protocols established
by the Fourth Report.1 As a result, the authors of this
study suggest repeating blood pressures that are initially elevated.
Once the blood pressure is obtained, it should
be classified by percentile based on age, sex and
height percentile, as determined by the revised CDC
growth charts.4 Because these charts may be cumbersome to use in practice, a simplified table was
created to identify cutoffs for children and adolescents needing further evaluation.6 A more simplified blood pressure table was developed for children
ages 3–18 for providers in the outpatient setting by
Mitchell et al to improve recognition of pediatric
hypertension in the outpatient setting. Blood pressure
elevations that exceed these levels should prompt
referral to standardized tables to confirm a diagnosis of hypertension.7 On-line, web-based calculators
also exist that can classify blood pressure by percentile to quickly and appropriately classify children
and adolescents. An example of one online calculator can be found at Baylor College of Medicine Body
Composition Lab in Houston, Texas.8
Although less is known about the long-term consequences of hypertension in children and adolescents,
elevated blood pressure in childhood and adolescence
is a risk factor for hypertension and cardiovascular
disease in adults and may be associated with left ventricular hypertrophy (LVH) at the time of diagnosis.4
Primary hypertension, once felt to be rare in children,
is now considered to be about five times more common
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than secondary hypertension. Primary hypertension is
more common in older children and adolescents and
is usually characterized by Stage 1 hypertension.4 It is
commonly associated with a family history of hypertension or cardiovascular disease.9 Secondary causes
of hypertension are more common in children less
than 6 years of age and are usually renal or renovascular in origin.10
The Fourth Report outlines the recommended
clinical evaluation for children and adolescents with
confirmed hypertension. (See Table 1) One of the key
aspects of this evaluation is to identify the presence of
co-morbidities that may alter treatment goals for individual patients. Attention should be paid to the recognition of sleep apnea since it may be associated with
higher blood pressure in children and adolescents and
it is more common in the overweight. In addition,
echocardiography is recommended at time of diagnosis to determine if LVH is present. The presence of
LVH is a marker for target-organ damage and an indication for more aggressive therapy. Table 2 outlines
frequency of BP measurement and indications for
therapeutic lifestyle changes and/or pharmacotherapy
based on stage of hypertension.
In general, the goal of therapy is to reduce the
blood pressure to less than the 95th percentile in
children and adolescents with no co-morbidities.4
Some experts recommend a goal of less than the 90th
percentile for this group.5 In the setting of chronic
kidney disease, diabetes or target-organ damage such
as LVH, the goal BP is less than the 90th percentile
for sex, age, and height.4 There may be a role for
lowering blood pressure below the 75th percentile in
patients with proteinuria.5
Nonpharmacologic management of hypertension
includes weight loss, aerobic exercise, restriction
of salt intake, and stress reduction.11,12 Overweight
increases the risk for the development of hypertension
significantly.2,5 Although there is limited evidence,
types of aerobic exercise thought to be most beneficial are walking, running, cycling, or swimming.
The high degree of patient and family commitment required may limit their effectiveness.13 During aerobic exercise, peripheral vascular resistance
decreases, causing an increase in systolic blood pressure (SBP) and mean arterial pressure (MAP) and
a reduction in the diastolic blood pressure (DBP);

however, in static exercise such as weight lifting,
the SBP, DBP, and MAP increase significantly and
can exceed the values for aerobic exercise. There are
usually both components in exercise so participation
should only be granted when the demands for
training and participating in the activity have been
examined and determined that the child is not at risk
for a catastrophic event from an abrupt increase in
BP.11 The preparticipation physical evaluation working group recommends those with Stage 2 hypertension avoid heavy weight and power lifting,
bodybuilding, strength training and other high-static
component sports. Those with sustained Stage 1
hypertension need individualized evaluation prior to
participation.14
The DietaryApproaches to Stopping Hypertension,
or DASH diet, is recommended although its effectiveness in children and adolescents with essential
hypertension has not been extensively studied.15
The diet emphasizes the intake of fruits, vegetables,
low-fat dairy and whole grains and limits intake of
high fat foods and refined sugar. It has been shown
to be effective in adults to reduce blood pressure and has no real side effects.12 One study did
review incorporation of the DASH diet in children
with diabetes and hypertension and demonstrated
a substantial reduction in the propensity of Type 1
diabetic children to have hypertension but this was
not observed in those with Type 2 diabetes.16 Most
of the children with Type 2 diabetes were obese in
the study which may explain the lack of improvement in this population.
While these therapies may be effective in reducing the blood pressure to the targeted levels, pharmacologic therapy will need to be considered if they
do not. The etiology of the hypertension, the anticipated benefits for the child, and the potential adverse
effects should guide the choice of medication.4,17
Given the lack of long-term pediatric data on benefits
of therapy and adverse effects on growth and development, medications should be started cautiously.18
First line antihypertensive medications for children
include angiotensin-converting enzyme inhibitors
(ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), beta-blockers (BBs)
and diuretics. Treatments specific for secondary
causes of hypertension and severe hypertension are
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Table 1. Clinical evaluation of confirmed hypertension.
Study or procedure
Evaluation for identifiable causes
History, including sleep history,
family history, risk factors, diet, and
habits such as smoking and drinking
alchohol; physical examination
BUN, creatinine, electrolytes,
urinalysis, and urine culture
CBC
Renal U/S
Evaluation for comorbidity
Fasting lipid panel, fasting glucose

Drug screen
Polysomnography
Evaluation for target-organ damage
Echocardiogram
Retinal exam

Further evaluation as indicated
Ambulatory BP monitoring

Purpose

Target population

History and physical examination
help focus subsequent evaluation

All children with persistent BP $ 95th
percentile

R/O renal disease and chronic
pyelonephritis
R/O anemia, consistent with chronic
renal disease
R/O renal scar, congenital anomaly,
or disparate renal size

All children with persistent BP $ 95th
percentile
All children with persistent BP $ 95th
percentile
All children with persistent BP $ 95th
percentile

Identify hyperlipidemia, identify
metabolic abnormalities

Overweight patients with BP at
90th–94th percentile; all patients with
BP $ 95th percentile. Family history
of hypertension or cardiovascular
disease. Child with chronic renal
disease
History suggestive of possible
contribution by substances or drugs
History of loud, frequent snoring

Identify substances that might cause
hypertension
Identify sleep disorder in association
with hypertension
Identify LVH and other indications of
cardiac involvement
Identify retinal vascular changes

Identify white-coat hypertension,
abnormal diurnal BP pattern, BP
load

Plasma renin determination

Identify low renin, suggesting
mineralocorticoid-related disease

Renovascular imaging
• Isotopic scintigraphy (renal scan)
• Magnetic resonance angiography
• Duplex Doppler flow studies
• 3-Dimensional CT
• Arteriography: DSA or classic
Plasma and urine steroid levels

Identify renovascular disease

Plasma and urine catecholamines

Identify steroid-mediated
hypertension
Identify catecholamine-mediated
hypertension

Patients with comorbid risk factors*
and BP 90th–94th percentile; all
patients with BP $ 95th percentile
Patients with comorbid risk factors*
and BP 90th–94th percentile; all
patients with BP $ 95th percentile
Patients in whom white-coat
hypertension is suspected, and when
other information on BP pattern is
needed
Young children with Stage 1
hypertension and any child or
adolescent with Stage 2 hypertension
Positive family history of severe
hypertension
Young children with Stage 1
hypertension and any child or
adolescent with Stage 2 hypertension

Young children with Stage 1
hypertension and any child or
adolescent with Stage 2 hypertension
Young children with Stage 1
hypertension and any child or
adolescent with Stage 2 hypertension

Notes: *Comorbid risk factors also include diabetes mellitus and kidney disease. Reproduced with permission from Pediatrics, Vol. 114, Page 562,
copyright 2004 by the AAP.
Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; CBC, complete blood count; CT, computerized tomography; DSA, digital subtraction
angiography; LVH, left ventricular hypertrophy; R/O, rule out; U/S, ultrasound.
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90th to , 95th or if BP
exceeds 120/80 mmHg
even if below 90th
percentile up to , 95th
percentile†

95th percentile to the 99th
percentile plus 5 mmHg

. 99th percentile plus
5 mmHg

Prehypertension

Stage 1
hypertension

Stage 2
hypertension

Evaluate or refer to source
of care within 1 week or
immediately if the patients is
symptomatic

Recheck in 1–2 weeks
or sooner if the patient is
symptomatic; if persistently
elevated on two additional
occasions, evaluate or refer to
source of care within 1 month

Recheck in 6 months.

Recheck at next scheduled
physical examination

Frequency of BP
measurement

None unless compelling
indications such as CKD,
diabetes mellitus, heart
failure, or LVH exist
Initiated therapy based on
indications in Tables 6 or
if compelling indications
as above

Initiate therapy§

Weight-management
counseling if overweight,
introduce physical activity
and diet management‡

Weight-management
counseling if overweight,
introduce physical activity
and diet management‡

–

Pharmacologic therapy

Weight-management
counseling if overweight,
introduce physical activity
and diet management‡

Encourage healthy diet,
sleep, and physical
activity

Therapeutic lifestyle
changes

Notes: *For sex, age and height measured on at least three separate occasions; if systolic and diastolic categories are different, categorize by the higher value.
†
This occurs typically at 12 years old for SBP and at 16 years old for DBP.
‡
Parents and children trying to modify the eating plan to the Dietary Approaches to Stop Hypertension (DASH) eating plan could benefit from consultation with a registered or licensed
nutritionist to get them started.
§
More than one drug may be required.
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
Reproduced with permission from Pediatrics, Vol. 114, page 560, Copyright 2004 by the AAP.

, 90th

Normal

SBP or DBP percentile*

Table 2. Classificiation of hypertension in children and adolescents, with measurement frequency and therapy recommendations.
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beyond the scope of this article. Hypertension will
refer to essential or primary hypertension for the
remainder of the article unless specified otherwise.

Mechanism of Action, Metabolism,
and Pharmacokinetic Profile

Most pharmacokinetic data for children has come from
adult trials. With the passage of the Food and Drug
Administration Modernization Act in 1997, there has
been an increase in pharmaceutical-sponsored trials
evaluating antihypertensive medications in children.
This was reinforced with The Best Pharmaceutical
for Children Act passed in 2002 and expanded by the
Pediatric Research Equity Act passed in 2003 requiring all applications for new drugs to include pediatric
assessment data unless the pharmaceutical company
obtained a waiver or deferral.12

Angiotensin-Converting enzyme
inhibitors and angiotensin receptor
blockers

ACEIs are one of the most commonly used antihypertensive medications in the pediatric population. In
general, they have few adverse effects in standard doses
and have convenient dosing schedules to improve
adherence. This makes them attractive choices for
pediatric hypertension especially in adolescents.19
Angiotensin-converting enzyme (ACE) facilitates
the conversion of angiotensin I to angiotensin II and
the degradation of bradykinin. Angiotensin receptor
blockers
(ARBs)
selectively
inhibit
the
binding of angiotensin II to the angiotensin II type 1
receptors.19
Angiotensin II produces arterial vasoconstriction
and activation of the renin-angiotensin system promoting salt and water reabsorption in the distal tubules
mediated by aldosterone. Angiotensin II also stimulates the sympathetic nervous system and has a direct
inotropic effect on the heart. Bradykinin produces
vasodilatation via prostaglandin-mediated effects on
endothelial cells. ACEIs prevent the conversion of
angiotensin I to angiotensin II which reduces arterial vasoconstriction and the salt and water retention
facilitated by stimulation of aldosterone release by
angiotensin II and with reduced degradation of bradykinin, arterial vasodilation. Blood pressure falls
gradually until ACE is inhibited by 90% rather than
in a dose response effect.20–23 Angiotensin II produces
18

vasoconstriction at both the afferent and efferent
arterioles with preferential increases at the efferent
arteriole; therefore ACEIs increase blood flow to the
kidney despite lowering blood pressure. Additionally,
the sulfhydryl group present on captopril is thought to
have an anti-inflammatory effect.24 ACEIs are separated by their route of elimination, presence of a sulfhydryl group, and requirement for activation.20

Calcium channel blockers

Calcium channel blocking antihypertensives inhibit
the influx of extracellular calcium into the cellular
membrane of the smooth muscle and other contractile cells by blocking the transmembrane transport of
calcium. This results in reduced contractility and arteriolar smooth muscle tone in a dose-dependent fashion.
Dihydropyridines are the major class of CCBs used
to treat essential hypertension in children because of
their relative selectivity for arteriolar smooth muscle.
These include amlodipine, isradipine, and nifedipine.
The non-dihydropyridines, another class of CCBs
that includes verapamil and diltiazem, have greater
affinity for cardiac cells thus reducing contractility
and altering conduction at the sinus node pacemaker
and atrioventricular node respectively. Additionally,
increases in glomerular filtration rate (GFR) and renal
blood flow occur with therapy presumably related
to the reduction in renal vascular resistance.11,19–21,23
Non-dihydropyridines are rarely used for the treatment
of essential hypertension in children and adolescents
because of their effects on cardiac functioning.22

Beta-Blockers

Beta-adrenergic antagonists reduce the effect of
endogenous catecholamines on beta-adrenergic
receptors. There are three identified types of receptors
designated β1, β2, and β3. β1-adrenergic receptors are
found primarily in the heart and kidney; β2-adrenergic
receptors are located in multiple areas particularly the lung, vascular smooth muscle, and skeletal muscle; and β3-adrenergic receptors are located
in adipose tissue.21 In general, BBs competitively
block β1-adrenergic receptors and β2-adrenergic
receptors dependent upon the selectivity of the individual drug.19 These medications are separated by
several characteristics, including cardioselectivity,
alpha adrenergic activity, hydrophilic and lipophilic
properties and intrinsic sympathomimetic activity.
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 ssessment of these properties can be useful in
A
selecting the appropriate BB for use in a particular
patient.11
Included in this category are BBs that also have
α-adrenoreceptor blocking properties. They exert
their effect primarily by competitive blockade of
peripheral post-synaptic alpha1-receptors producing vasodilation.19–21 Nonselective beta-blocker use
has been associated with development of diabetes in
contrast to the cardioselective β-antagonists.25

Diuretics

Diuretics are used primarily as a second medication
when adequate blood pressure has not been attained
with monotherapy especially in adolescents and in
children with renal disease with high volume states.
The two types primarily used are thiazide and loop
diuretics. Thiazide diuretics exert their effect on the
distal tubule in the kidney to decrease sodium and
water reabsorption and increase potassium secretion in an ion exchange mechanism by inhibiting the
sodium-chloride membrane transporter. With long term
use, the thiazides produce vasodilatation. Although
the mechanism of action is not thoroughly understood, it is postulated it may be due to a decrease in
interstitial volume, a decrease in intracellular sodium
that alters intracellular calcium, or a change in cellular receptors to vasoconstrictor substances. Therefore, initial blood pressure reduction appears to occur
due to a decrease in plasma volume and cardiac output and then occurs due to a reduction in peripheral
resistance. Their efficacy is dependent on the glomerular filtration rate (GFR). They are most efficacious
when the GFR is .50 ml/minute and ineffective when the GFR is ,30 ml/minute.19–21 Thiazide
diuretics produce elevations in blood glucose and
insulin levels.26
Loop diuretics exert their effect at the ascending
limb of the loop of Henle by decreasing the reabsorption of sodium and water by inhibiting the sodiumpotassium-chloride membrane transporter. They
also increase renal blood flow by reducing renovascular resistance. They are more potent than thiazide
diuretics but their efficacy also decreases as GFR is
reduced.19,20
Please see Table 3 for information related to peak
level, half life, and excretion. Clinicians should be
aware that not all of these medications have specific

pediatric FDA approval or labeling. Dosage information should be confirmed prior to use.

Clinical Studies, Safety and Efficacy

Angiotensin converting enzyme
inhibitors
Safety and efficacy data are available for most of the
ACEI. Enalapril and lisinopril both produce a dosedependent reduction in blood pressure. Minimum
effective dosages range from 0.08 mg/kg/day to
0.6 mg/kg/day and were well tolerated.12,27,28 However,
fosinopril did not produce the same dose response
reduction in blood pressure as that seen in the enalapril and lisinopril studies, but did demonstrate a
significant reduction in SBP and DBP. The study participants were ages 6–16 years of age. Fosinopril is
only recommended for children weighing $50 kg.12,29
Ramipril studied in children with chronic renal disease reduced the BP at 24 hours at a daily dose of
6 mg/m2 and at a dose of 2.5 mg/m2 reduced BP and
proteinuria in children with essential hypertension
and in those with chronic kidney disease.5
Common side effects associated with ACEI medications include hypotension, cough, hyperkalemia
and elevated creatinine. Monitoring of serum electrolytes and creatinine are recommended with initiation
of therapy and periodically to monitor the potassium
and creatinine.
Other adverse reactions include angioedema,
headache, anemia, tachycardia, vertigo, dyspnea,
rash, and leucopenia.27,28 One study found that children between 2–16 years of age receiving enalapril
or captopril developed neutrophilic hypersegmentation.30 One retrospective study of lisinopril found
no effect on age-specific growth patterns despite
the varying medical conditions of the participants.28
A meta-analysis of studies evaluating ethnic differences in children treated with ACEI suggested a
difference between black and white children to the
antihypertensive effects of ACEI. Black children
demonstrated a lesser antihypertensive response
than white children.31 ACEI are contraindicated in
patients with bilateral renal artery stenosis.
Infants have an exaggerated response to ACEIs and
should receive smaller weight-adjusted dosages than
older children. This may be related to their dependence
on the renin-angiotensin-aldosterone system for maintenance of renal blood flow. They can have severe,
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Table 3. Pharmacologic therapy.
Drug
Ace Inhibitors
Benazepril (prodrug)
Captopril
Fosinopril (prodrug)
Lisinopril
Quanapril (prodrug)

Peak level

Half Life

Excretion

Dosing
schedule

2–4 h
1–2 fasting

5h

Renal
(11%–12% biliary)
Urine
Urine = Bile/Feces
Urine
Bile/Feces 37%
Urine 61%
Bile/Feces 33%
Urine 60%

QD

3h
5–6 h
1–2 h

3h
11–13 h
12 h
2 h (elimination)
25 (terminal)
14h ages 12–16
. 16 h ages 6– , 12

TID
QD
QD
QD

 Enalapril (prodrug)

3–4 h

ARBs
Candesarten (prodrug)

4h

6 h ages 1–17

Irbesartan

1–2 h

11–15 h

Olmesartan (prodrug)

1.4–2.6 h

12–18 h

Telmisartan
Losartan

1–1.5 h
1–2 h

27–28 h
4–5 h

 Valsartan

2–3 h

6h

Calcium channel blockers
Amlodipine
Nifedipine
Isradipine

6–12 h
25–30 min
1.5 h

36–45 h
2h
9h

Urine
Urine
Bile/Feces 25%–30%
Urine 60–65%

QD
QD-BID
QD

1–3 h
2–4 h

4–6 h
6–7 h
3–7 h
6–8 h

BID-TID
QD-BID
BID
BID

3h

7–15 h

Urine
Urine
Bile/Feces
Bile/Feces 50%
Urine 50%
Urine

2–4 h
1–2 h

5–15 h
24 h

Beta blockers
Propranolol (non-selective)
Atenolol (selective)
Metropolol (selective)
 Labetalol (selective alpha; nonselective beta)
Bisoprolol (selective)
Diuretics
Hydrochlorothiazide
Furosemide

Bile/Feces 67%
Urine 33%
Bile/Feces 80%
Urine 20%
Bile/Feces 60%
Urine 3%–15%
Bile/Feces
Bile/Feces 60%
Urine 35%
Bile/Feces 83%
Urine 13%

Urine
Bile/Fsssseces 12%
Urine 88%

QD-BID
QD
QD
QD
QD
QD
QD

QD
QD
QD

4,12,19, 20, 24, 29, 32, 33, 35, 36, 38, 41, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61.

prolonged hypotension with oliguric renal failure.27 In
a study with children at least 6 months of age, captopril was given in dosages of 0.5, 1.0, and 2.0 mg/kg.
Reductions in SBP and DBP were similar and independent of dosage; therefore, a dosage of 0.5 mg/kg is recommended as the starting dose in children $6 months
of age.21 ACEI should be avoided in pregnancy and
used cautiously in those of child-bearing age. ACEI
exposure during the first trimester can result in major
congenital malformations. Exposure during the
second and third trimesters is associated with fetal
20

hypotension, growth restriction, pulmonary and renal
hypoplasia, anuria, and death.11,27
Angiotensin receptor blockers
Several studies have demonstrated the efficacy of
ARBs in the treatment of hypertension in children.
In a systematic review, the ARBs irbesartan, candesartan, and losartan lower SBP and DBP, 10.5 mmHg
and 6.9 mmHg respectively. They decrease proteinuria by over 50% as well. Losartan reduced DBP in a
dose dependent fashion at doses from 0.75 mg/kg/day
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to 1.44 mg/kg/day and was well tolerated. A small
irbesartan study indicated that doses of 75–150 mg/day
were efficacious in the treatment of hypertension but
a later study in children ages 6–16 years failed to
show a significant antihypertensive effect.5,12,32 In the
Assessment of Efficacy and Safety of Olmesartan in
Pediatric Hypertension (AESOP) study, two groups
of children ages 6–16 years of age were enrolled
and given either low-dose (2.5–5 mg) or high dose
(20–40 mg) Olmesartan daily for three weeks. Both
groups demonstrated statistically significant reductions in SBP and DBP but much greater in the highdose group.33 Valsartan demonstrated efficacy in
reducing blood pressure in children aged 1–5 years.
During this study conducted in four phases, the children were randomized to receive low-dose, mediumdose, or high-dose valsartan. The fourth phase was a
52 week open label treatment period. Valsartan significantly lowered SBP and DBP in all of the dosage groups regardless of race or weight. During the
open-label phase, participants received either valsartan alone or combined with hydrochlorothiazide.
By the end of the period, .75% achieved a SBP less
than the 95th percentile.34,35 Telmisartan at dosages of
1–2 mg/kg produced significant reductions in SBP in
children ages 6 to ,18 years of age.36
Generally, ARBs are well tolerated. Side effects
reported included cough, rhinitis, urinary and gastrointestinal infections, headache, dizziness, blurred
vision, fatigue, anemia, and hyperkalemia.32 Other
adverse reactions reported include rash and pruritus, hypertriglyceridemia, edema, leucopenia, and
thrombocytopenia.34
The same precautions should be taken in pregnancy
and in women of child-bearing age as with ACEI.
Similar congenital malformations seen with ACEI
exposure during pregnancy have been reported.32
Studies involving candesartan, losartan, and valsartan
showed no effect on growth during study periods of
52 weeks for each.32,34
Calcium channel blockers
The major class of CCBs used in the treatment
of pediatric hypertension is the dihydropyridines
because of their rather selective action on arteriolar
smooth muscle.11 Amlodipine, nifedipine, felodipine,
nicardipine, and isradipine have shown efficacy in
treating hypertension in children.20 Several trials

have studied the efficacy of amlodipine in the
treatment of pediatric hypertension. In one study, dosages of 0.06–0.34 mg/kg/day effectively reduced SBP
in children ages 6 to 16.5 In a prospective study evaluating amlodipine, 21 children were given dosages
based on weight: 5 mg/kg/day for children .70 kg;
2.5 mg/kg for those 50–70 kg; and 0.05 mg/kg for
those ,50 kg. Dosing was once daily. The 16 children with primary hypertension reached their target
BP of ,95th percentile for age, weight, and gender.21
Long-acting nifedipine might be an option in older
children that can swallow tablets but it cannot be
crushed; therefore, its use is limited in young children.21 Nicardipine is similar to nifedipine except it
does not affect cardiac function. Typically nicardipine
and isradipine are delivered by continuous intravenous infusion because of their short half-lives. They
can be rapidly titrated to a desired BP.27 A mean effective nicardipine dose of 1.8 ± 1.0 µ/kg/min achieved
a 16% drop in SBP, 23% in DBP, and a 7% increase
in heart rate within 2.7 ± 2.1 hours after initiation.37
However, the oral preparation of isradipine was given
to 12 children over a three year period. There were
6 boys and 6 girls, ranging in age of 10 months to
11 years. Initial doses were given at 0.1 mg/kg for all
children and increased every 3–6 doses until the SBP
and DBP were reduced to two standard deviations for
their age. Dosing was either every 6 or 8 hours per day.
The SBP was reduced 20% and the DBP 28% from
initial parameters at doses of 0.6 ± 0.3 mg/kg/day. As
with nicardipine, isradipine causes cerebral vasodilation and must be used cautiously in children with
intracranial pathology if at all.27,38
The most common adverse side effects reported
with the use of CCBs include peripheral edema,
dizziness, flushing, nausea, headache, and postural
hypotension. Other reported adverse events include
gingival hyperplasia, chest pain, nausea and vomiting, and reflex tachycardia seen with nifedipine. Side
effects are seen more commonly as maximum dosages of the drugs are reached.11,21,27
Beta-Blockers
There are limited studies evaluating BBs in children.
Additionally, the variability of pharmacologic properties of drugs in this group and characteristics of
each individual drug influence the selection of medication. There are few studies evaluating propranolol,

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2012:6

21

Stephens et al

a nonselective beta-blocker, as an antihypertensive in
children. It has been used to treat hypertension for
several years with much of the data extrapolated from
studies in normotensive children with cardiac disease
or portal hypertension.5 Effective dosages range from
1 to 6 mg/kg/day. In one study of 11 children ages
7 months to 16 years receiving 2.5 mg/kg/day, SBP
was reduced by an average of 26 mmHg and DBP
by an average of 20 mmHg.19,21 Atenolol, metoprolol,
and bisoprolol are more cardioselective beta adrenergic antagonists. Atenolol is a β1-selective adrenergic
antagonist that can be dosed once daily with recommended doses of 1–2 mg/kg/day. It is as potent as
propranolol when compared on a weight-by-weight
basis and has demonstrated efficacy in adolescents.19,24
Metoprolol succinate in an extended release preparation and was studied in two phases, a 4 week treatment period and an open-label maintenance period
for 52 weeks in children ages 6–16 years of age.
Metoprolol is cardioselective but has no intrinsic sympathomimetic activity. The greatest reduction in SBP
occurred at a dose of 1 mg/kg and for DBP; reductions were greatest at 2 mg/kg compared to placebo.
Results were seen independent of age, race, sexual
maturity, or gender. More overweight children had a
somewhat reduced response.39 Metoprolol reduces the
blood pressure and heart rate response in exercise and
reduces the sympathetic responses to mental stress
but does not impact endurance.21 Bisoprolol fumarate
was studied in combination with hydrochlorothiazide
(HCT) in children ages 6–17 years of age with Stage 1
hypertension over an eight week period. The group
receiving the β1-cardioselective beta blocker in combination with the thiazide (HCT) diuretic achieved a
reduction in SBP of 6.8% and DBP of 8.5% but those
that reached the target BP , 90th percentile were not
significantly different from placebo (45% vs. 34%).
Unfortunately there was also a significant placebo and
dropout rate in this trial.40 Labetalol possesses additional properties besides beta blockade. Labetaolol is
not cardioselective, has no intrinsic sympathomimetic
properties, but has significant α-adrenergic blockage.
The ratio of α to β blockade is estimated at seven to
one. It has been used both orally and intravenously
for severe hypertension.20 The α-adrenergic blockade
counteracts the increase in systemic vascular resistance caused by β2-antagonism. In a trial of 27 boys
22

evaluating labetalol infusion for hypertensive crisis
in children #24 months of age, labetalol produced a
mean BP reduction of 20% within 8 hours.41 Similar
results were obtained in children unable to tolerate
oral medications that were administered labetalol
by infusion.19
Side effects attributable to propranolol include
bradycardia, hypoglycemia, anorexia, asthma exacerbations, night terrors, and heart block.19,21 The most
common side effects noted in the metoprolol succinate and bisoprolol trials were headache but other
side effects reported were fatigue, upper respiratory
tract infection, cough, nasopharyngitis, diarrhea,
and dizziness.39,40 Labetalol can produce orthostatic
hypotension and syncope because of reduction in the
peripheral vascular resistance.20
Additional side effects attributable to BBs include
fatigue, cold extremities, and sexual dysfunction.20
Lipophilic BBs exert more central nervous system
side effects and β1-selective blocking agents have less
adverse effects on the lungs.24
Diuretics
There is a paucity of studies examining the use of
diuretics for essential hypertension in children. In one
study of 12 children ages 3–15 years involving chlorthalidone, statistically significant decreases in SBP
and DBP occurred. High dose hydrochlorothiazide
(50–100 mg) compared to clonidine improved BP
in adolescents but not to the degree of the comparison medication.20 Thiazide diuretics are more commonly used as adjunct therapy when monotherapy
has failed to achieve the desired BP targets because of
their synergistic effects with other antihypertensive
medication. They particularly are recommended for
adolescents in combination medications to improve
adherence.5 Thiazide diuretics are ineffective when
the GFR is ,30% from normal levels.21
Common side effects of diuretics relate to their
effects on fluid and electrolyte balance; therefore
serum electrolytes and creatinine should be monitored. Hypokalemia, volume contraction ± hypotension, anorexia, nausea and vomiting, pancreatitis,
and elevated uric acid levels have been reported as
well as ototoxicity with the use of loop diuretics.11
Table 4 summarizes key safety information based on
drug class.
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Table 4. Safety and monitoring of phamacologic therapy.
Ace inhibitors/ARBs
 All contraindicated in pregnancy
Use caution in females of childbearing age
Monitor potassium and creatinine
 Limited FDA approval to $6 years of age and to children
with creatinine clearance $30
Calcium channel blockers
Watch for postural hypotension, flushing, and edema
Beta blockers
May cause bradycardia-may limit dosing
May impact athletic performance
Avoid in insulin-dependent diabetics
 Non-cardioselective agents contraindicated in asthma
and heart failure
Diuretics
Monitor electrolytes upon initiation and periodically
 Watch for hyperkalemia with potassium sparing diuretics
4, 11, 20, 21, 27, 42

Place in Therapy and Patient
Preference

There are no adequate trials of antihypertensive medications in children that compare the effectiveness of
specific antihypertensives or classes of antihypertensives on key clinical endpoints.4 Since pediatric trials do demonstrate the ability of these medications
to lower blood pressure, the choice of specific agent
is left to the discretion of the physician who should
take into account patient preferences as well as other
clinical considerations. The ability of the patient to
swallow pills, ease of dosing and risk of pregnancy
should be considered. Certain co-morbidities that
favor certain classes of drugs include the use of an
ACE or ARB in patients with diabetes and microalbuminuria or proteinuric renal disease. Beta-blockers
and calcium channel blockers should be considered in
patients with migraine. In general, black children and
adolescents do not respond as well to ACEIs at standard doses.31 Beta-blockers must be used with caution or avoided in patients with asthma and a reliable
method of birth control must be in place for sexually
active adolescents on ACEs or ARBs. Cough does not
appear to limit the use of ACEs or ARBs in children
and adolescents as it does in adults.42
In general, the child or adolescent should be started
on the lowest recommended dose for the specific
medication and it should be titrated up, typically every
2–4 weeks, until target BP is reached or side effects

limit its use.4,5 After maximum doses are reached, a second
drug can be added if the BP is still not at goal.4 The
European guidelines recommend switching to another
class of drugs as an alternative approach if goal BP is
not achieved at maximum doses of a single agent.5
The Fourth Report recommends that consideration
should be given to using a second agent with complementary actions to the first. Examples include ACE
inhibitors and diuretics, or a vasodilator with a diuretic or
beta-blocker. There is limited data and practical experience with use of fixed-dose combination medications.4
Children and adolescents may be considered for stepdown therapy if blood pressure remains well controlled,
especially if they achieve significant weight loss.

Conclusion

Primary hypertension in children is increasing in
prevalence with many cases likely going undiagnosed.
Physicians need to screen children and adolescents
for hypertension during routine visits and use normative percentile data for diagnosis and classification.
Providers can consider referral for ambulatory blood
pressure monitoring to check for possible white coat
hypertension. Once the diagnosis is made, a clinical evaluation must be performed to identify the
presence of co-morbidities. Subsequent follow-up
blood pressure measurements, therapeutic lifestyle
changes and pharmacologic therapies are indicated
based on the stage of the disease. The goal of therapy is to reduce blood pressure to at least ,95% in
patients without comorbidities and ,90% in the presence of CKD, DM and target organ damage. Several
non-pharmacologic management strategies exist for
the treatment of primary hypertension and when they
are not effective, pharmacologic treatment needs to be
considered. The choice of a specific agent should take
into account clinical considerations and patient preferences. ACE inhibitors or ARBs are useful in children, especially those with diabetes or kidney disease
with proteinuria. Calcium channel blockers are also
a good option in patients with diabetes or metabolic
syndrome because they improve insulin sensitivity.
Diuretics are also reasonable choice, although may not
be as effective as monotherapy. Beta-blockers should
usually be saved for second-line therapy given their
side effect profiles, but consider them for children
and adolescents with an additional indication such
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as migraines or tachycardia. In general, physicians
should start with the lowest recommended dose and
titrate every 2–4 weeks. If target blood pressure is not
reached, physicians can switch to a new agent or add
a complementary agent.

Disclosures

Author(s) have provided signed confirmations to the
publisher of their compliance with all applicable legal
and ethical obligations in respect to declaration of
conflicts of interest, funding, authorship and contributorship, and compliance with ethical requirements
in respect to treatment of human and animal test
subjects. If this article contains identifiable human
subject(s) author(s) were required to supply signed
patient consent prior to publication. Author(s) have
confirmed that the published article is unique and not
under consideration nor published by any other publication and that they have consent to reproduce any
copyrighted material. The peer reviewers declared no
conflicts of interest.

References

1. Podoll A, Grenier M, Croix B, Feig D. Inaccuracy in pediatric outpatient
blood pressure measurement. Pediatrics. 2007;119:e538–43.
2. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Blood pressure differences by ethnic group among United States children and adolescents.
Hypertension. 2009;54:502–8.
3. Falkner B, Lurbe E, Schaefer F. High blood pressure in children: clinical and health policy implications. J Clin Hypertens. 2010;12(4):
261–76.
4. U.S. Department of Health and Human Services, National Institutes of
Health, National Heart, Lung, and Blood Institute. The Fourth Report on the
Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children
and Adolescents. Available at: http://nhlbi.nih.gov/health/prof/heart/hbp/
hbp_ped.pdf. Verified October 2011.
5. Lurbe E, Cifkova R, Cruickshank J, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society
of Hypertension. J Hypertens. 2009;27:1719–42.
6. Kaelber D, Pickett F. Simple table to identify children and adolescents needing further evaluation of blood pressure. Pediatrics. 2009;123:e972–4.
7. Mitchell C, Theriot J, Sayat J, Muchant D, Franco S. Reducing the complexity of pediatric hypertension: Use of blood pressure screening tool
to improve recognition of elevated blood pressure in children. Journal of
Paediatrics and Child Health. 2011;47:22–6.
8. USDA/ARS Children’s Nutrition Research Center, Baylor College of
Medicine, Houston, Texas. http://www.bcm.edu/bodycomplab/Flashapps/
BPVAgeChartpage.html. Accessed December 11, 2011.
9. Hellekson K. Report on the diagnosis, evaluation, and treatment of
high blood pressure in children and adolescents. Am Fam Physician.
2005;71(5):1014–9.
10. Andrade H, Antonio N, Rodrigues D, Da Silva A, Pego M, Providencia L.
Hipertensão arterial sistémica em idade pediátrica [High Blood pressure in
the pediatric age group]. Rev Port Cardiol. 2010;29(03):413–32.
11. Feld L, Corey H. Hypertension in childhood. Pediatr Rev. 2007;28:
283–98.
12. Flynn J, Daniels S. Pharmacologic treatment of hypertension in children and
adolescents. J Pediatr. 2006;149:746–54.

24

13. Batisky D. Obesity and the role of lifestyle and dietary intervention in the
management of pediatric hypertension. J Med Liban. 2010;58(3):171–4.
14. Bernhardt DT, Roberts WO, editors. PPE Preparticipation Physical
Evaluation. 4th ed. Elk Grove, IL: American Academy of Pediatrics; 2010.
15. Kavey R, Daniels S, Flynn J. Management of high blood pressure in children
and adolescents. Cardiol Clin. 2010;28:597–607.
16. Günther A, Liese A, Bell R, et al. Association between the dietary
approaches to hypertension diet and hypertension in youth with diabetes
mellitus. Hypertension. 2009;53:6–12.
17. Hanevold C. Concepts guiding therapy for hypertension in children. Expert
Rev Cardiovasc Ther. 2009;7(6):647–57.
18. Lande M, Flynn J. Treatment of hypertension in children and adolescents.
Pediatr Nephrol. 2009;24:1939–49.
19. Robinson R, Nahata M, Batisky D, Mahan J. Pharmacologic treatment of
chronic pediatric hypertension. Pediatr Drugs. 2005;7(1):27–40.
20. Blowey D. Antihypertensive Agents: Mechanisms of action, safety profiles, and current uses in children. Curr Ther Res Clin Exp. 2001;62:
298–313.
21. Temple M, Nahata M. Treatment of pediatric hypertension. Pharmacotherapy.
2000;20(2):140–50.
22. Seikaly M. Hypertension in children: an update on treatment strategies.
Curr Opin Pediatr. 2007;19:170–7.
23. Garin E, Araya C. Treatment of systemic hypertension in children and
adolescents. Curr Opin Pediatr. 2009;21:600–4.
24. Seikaly M, Bahlawan-Seikaly S. Strategies of treatment of pediatric hypertension. J Med Liban. 2010;58(3):161–6.
25. Fonseca V. Effects of β-blockers on glucose and lipid metabolism. Curr
Med Res Opin. 2010;26(3):615–29.
26. Smith S, Anderson S, Wen S, et al. Lack of Correlation between thiazideinduced hyperglycemia and hypokalemia: subgroup analysis of results from
the pharmacogenomic evaluation of antihypertensive responses (PEAR)
study. Pharmacotherapy. 2009;29(10):1157–65.
27. Blowey D. Safety of the newer antihypertensive agents in children. Expert
Opin Drug Saf. 2002;1(1):39–43.
28. Raes A, Malfait F, Van Aken S, France A, Donckerwolcke R,
Vande Walle J. Lisionpril in paediatric medicine: a retrospective chart review
of long-term treatment in children. J Renin Angiotensin Aldosterone Syst.
2007;8(1):3–12.
29. Li J, Berezny K, Kilaru R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension.
2004;44:289–93.
30. Okutan V, Kürekçi A, Sarici S, et al. Neutrophil hypersegmentation in children receiving angiotensin converting enzyme inhibitors. Turk J Pediatr.
2008;50(5)438–42.
31. Li J, Baker-Smith C, Smith P, et al. Racial difference in blood pressure
response to angiotensin-converting enzyme inhibitors in children: a metaanalysis. Clin Pharmacol Ther. 2008;84(3):315–9.
32. Herder S, Weber E, Winkemann A, Herder C, Morck H. Efficacy and safety
of angiotensin II receptor type 1 antagonists in children and adolescents.
Pediatr Nephrol. 2010;25:801–11.
33. Tocci G, Volpe M. Olmesartan medoxomil for the treatment of hypertension in children and adolescents. Vascular Health and Risk Management.
2011;7:177–81.
34. Flynn J, Meyers K, Neto J, et al. Efficacy and safety of the angiotensin
receptor blocker valsartan in children with hypertension aged 1 to 5 years.
Hypertension. 2008;52:222–8.
35. Meyers K, Behar B. Valsartan use in pediatric hypertension. Future Cardiol.
2011;7(2):151–9.
36. Wells T, Portman R, Norman P, Haertter S, Davidai G, Wang F. Safety,
efficacy, and pharmacokinetics of telmisartan in pediatric patients with
hypertension. Clinical Pediatrics. 2010;49(10):938–46.
37. Flynn J, Mottes T, Brophy P, Kershaw D, Smoyer, Bunchman T. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr.
2001;139(1):38–43.
38. Strauser L, Groshong T, Tobias J. Initial experience with isradipine for
the treatment of hypertension in children. South Med J. 2000;93(3):
287–93.

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2012:6

Hypertension in children and adolescents
39. Batisky D, Sorof J, Sugg J, et al. Efficay and safety of extended release
metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical
trial experience. J Pediatr. 2007;150:134–9.
40. Sorof J, Cargo P, Graepel J, et al. β-Blocker/thiazide combination for
treatment of hypertensive children: a randomized double-blind, placebocontrolled trial. Pediatr Nephrol. 2002;17:345–50.
41. Thomas C, Moffett B, Wagner J, Mott A, Feig D. Safety and efficacy of
intravenous labetalol for hypertensive crisis in infants and small children.
Pediatr Crit Care Med. 2011;12:28–32.
42. Baker-Smith C, Benjamin D, Califf R, Murphy M, Li J, Smith P. Cough
in pediatric patients receiving angiotensin-converting enzyme inhibitor and
angiotensin receptor blocker therapy in randomized controlled trials. Clin
Pharmacol Ther. 2010;87(6):668–71.
43. Hogg R, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr
Nephrol. 2007;22:695–701.
44. Wells T, Rippley R, Hogg R, et al. The pharmacokinetics of enalapril in
children and infants with hypertension. J Clin Pharmacol. 2001;41(10):
1064–74.
45. Hoy S, Keating G. Candesartan cilexetil In children and adolescents aged
1 to ,17 years with Hypertension. Am J Cardiovasc Drugs. 2010;10(5):
335–42.
46. Sakarcan A, Tenney F, Wilson J, et al. The pharmacokinetics of irbesartan in
hypertensive children and adolescents. J Clin Pharmacol. 2001;41:742–9.
47. Muir V, Keating G. Olmesartan Medoxomil in children and adolescents
with hypertension. Drugs. 2010;70(18):2439–47.
48. Blumer J, Batisky D, Wells T, Shi V, Solar-Yohay S, Sunkara G. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension.
J Clin Pharmacol. 2009;49:235–41.
49. Williams F, Herndon D, Kulp G, Jeschke M. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery
2011;149:231–9.
50. Blumer J, Daniels S, Dreyer W, et al. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting
enzyme inhibitor treatment. J Clin Pharmacol. 2003;43:128–32.
51. Federal Drug Administration. Lotensin [prescribing information]. East
Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2002. (http://
www.accessdata.fda.gov/drugsatfda_docs/label/2004/019851s028lbl.pdf;
Accessed October 12, 2011)

52. Drugs.com [Internet]. Atenolol. (http://www.drugs.com/pro/atenolol-tablets.
html; Updated November 2011; Accessed December 2011) Available from:
http://www.drugs.com/atenolol-tablets.html.
53. Drugs.com [Internet]. Bisoprolol-Hydrochlorothiazide. (http://www.drugs.
com/pro/bisoprolol-hydrochlorothiazide.html; Updated February 2011;
Accessed October 2011) Available from: http://www.drugs.com/pro/bisoprololhydrochlorothiazide.html.
54. Drugs.com [Internet]. Captopril. (http://www.drugs.com/pro/captopriltablets.html; Updated June 2011; Accessed October 2011) Available from:
http://www.drugs.com/captopril-tablets.html.
55. Drugs.com [Internet]. Cardene-Injection. (http://www.drugs.com/pro/
cardene-injection.html; Updated November 2010; Accessed October 2011)
Available from: http://www.drugs.com/cardene-injection.html.
56. Drugs.com [Internet]. Fosinopril. (http://www.drugs.com/pro/fosinopril.
html; Updated November 2011; Accessed October 2011) Available from:
http://www.drugs.com/fosinopril.html.
57. Drugs.com [Internet]. Hydrochlorothiazide. (http://www.drugs.com/pro/
hydrochlorothiazide.html; Updated October 2011; Accessed October 2011)
Available from: http://www.drugs.com/pro/hydrochlorothiazide.html.
58. Drugs.com [Internet]. Isradipine. (http://www.drugs.com/pro/isradipine.
html; Updated August 2007; Accessed October 2011) Available from: http://
www.drugs.com/pro/isradipine.html.
59. Drugs.com [Internet]. Labetalol. (http://www.drugs.com/pro/labetalol.html;
Updated February 2011; Accessed October 2011) Available from: http://
www.drugs.com/pro/labetalol.html.
60. Drugs.com [Internet]. Lisinopril. (http://www.drugs.com/pro/lisinopril.
html; Updated October 2011; Accessed October 2011) Available from: http://
www.drugs.com/pro/lisinopril.html.
61. Drugs.com [Internet]. Metoprolol-Succinate. (http://www.drugs.com/pro/
metoprolol-succinate.html; Updated September 2011; Accessed October
2011) Available from: http://www.drugs.com/pro/metoprolol-succinate.html.

Publish with Libertas Academica and
every scientist working in your field can
read your article
“I would like to say that this is the most author-friendly
editing process I have experienced in over 150
publications. Thank you most sincerely.”
“The communication between your staff and me has
been terrific. Whenever progress is made with the
manuscript, I receive notice. Quite honestly, I’ve
never had such complete communication with a
journal.”
“LA is different, and hopefully represents a kind of
scientific publication machinery that removes the
hurdles from free flow of scientific thought.”

Your paper will be:
•
Available to your entire community
free of charge
•
Fairly and quickly peer reviewed
•
Yours! You retain copyright
http://www.la-press.com

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2012:6

25

